Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Bid For Millennium May Face Several Hurdles – Pharma Analyst

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Several factors could still prevent Japan's top drug company Takeda from acquiring U.S.-based Millennium Pharmaceuticals, a pharmaceutical analyst said in an interview with PharmAsia News
Advertisement

Related Content

Astellas Pharma Branches Out In U.S., Offers Career-building Workshops To Employees
Astellas Pharma Branches Out In U.S., Offers Career-building Workshops To Employees
Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Advertisement
UsernamePublicRestriction

Register

SC068169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel